These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 30592773)

  • 61. A rapid HPLC-ESI-MS/MS method for determination of dihydrouracil/uracil ratio in plasma: evaluation of toxicity to 5-flurouracil in patients with gastrointestinal cancer.
    César IC; Cunha-Júnior GF; Duarte Byrro RM; Vaz Coelho LG; Pianetti GA
    Ther Drug Monit; 2012 Feb; 34(1):59-66. PubMed ID: 22210098
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Renal impairment and DPD testing: Watch out for false-positive results!
    Carriat L; Quaranta S; Solas C; Rony M; Ciccolini J
    Br J Clin Pharmacol; 2022 Nov; 88(11):4928-4932. PubMed ID: 35939355
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Genotyping of a family with a novel deleterious DPYD mutation supports the pretherapeutic screening of DPD deficiency with dihydrouracil/uracil ratio.
    Thomas F; Hennebelle I; Delmas C; Lochon I; Dhelens C; Garnier Tixidre C; Bonadona A; Penel N; Goncalves A; Delord JP; Toulas C; Chatelut E
    Clin Pharmacol Ther; 2016 Feb; 99(2):235-42. PubMed ID: 26265035
    [TBL] [Abstract][Full Text] [Related]  

  • 64. 5-Fluorouracil-related severe toxicity: a comparison of different methods for the pretherapeutic detection of dihydropyrimidine dehydrogenase deficiency.
    Boisdron-Celle M; Remaud G; Traore S; Poirier AL; Gamelin L; Morel A; Gamelin E
    Cancer Lett; 2007 May; 249(2):271-82. PubMed ID: 17064846
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Pretherapeutic screening for Dihydropyrimidine deshydrogenase deficiency in measuring uracilemia in dialysis patients leads to a high rate of falsely positive results.
    Gaible C; Narjoz C; Loriot MA; Roueff S; Pallet N
    Cancer Chemother Pharmacol; 2021 Dec; 88(6):1049-1053. PubMed ID: 34515833
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Preclinical development of eniluracil: enhancing the therapeutic index and dosing convenience of 5-fluorouracil.
    Paff MT; Baccanari DP; Davis ST; Cao S; Tansik RL; Rustum YM; Spector T
    Invest New Drugs; 2000 Nov; 18(4):365-71. PubMed ID: 11081572
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Is capecitabine safe in patients with gastrointestinal cancer and dihydropyrimidine dehydrogenase deficiency?
    Saif MW; Diasio R
    Clin Colorectal Cancer; 2006 Jan; 5(5):359-62. PubMed ID: 16512996
    [TBL] [Abstract][Full Text] [Related]  

  • 68. [Dihydropyrimidine dehydrogenase activity and its genetic aberrations].
    Ogura K
    Gan To Kagaku Ryoho; 2006 Aug; 33(8):1041-8. PubMed ID: 16912518
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Clinical implications of dihydropyrimidine dehydrogenase on 5-FU pharmacology.
    Diasio RB
    Oncology (Williston Park); 2001 Jan; 15(1 Suppl 2):21-6; discussion 27. PubMed ID: 11219973
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Correlation between dihydropyrimidine dehydrogenase activity in peripheral mononuclear cells and systemic clearance of fluorouracil in cancer patients.
    Fleming RA; Milano G; Thyss A; Etienne MC; Renée N; Schneider M; Demard F
    Cancer Res; 1992 May; 52(10):2899-902. PubMed ID: 1581906
    [TBL] [Abstract][Full Text] [Related]  

  • 71. High-performance liquid chromatographic assay with UV detection for measurement of dihydrouracil/uracil ratio in plasma.
    Déporte R; Amiand M; Moreau A; Charbonnel C; Campion L
    J Chromatogr B Analyt Technol Biomed Life Sci; 2006 Apr; 834(1-2):170-7. PubMed ID: 16545990
    [TBL] [Abstract][Full Text] [Related]  

  • 72. The effect of chemotherapy or radiotherapy on thymidine phosphorylase and dihydropyrimidine dehydrogenase expression in cancer of the uterine cervix.
    Hasegawa K; Okamoto H; Kawamura K; Kato R; Kobayashi Y; Sekiya T; Udagawa Y
    Eur J Obstet Gynecol Reprod Biol; 2012 Jul; 163(1):67-70. PubMed ID: 22480411
    [TBL] [Abstract][Full Text] [Related]  

  • 73. [Combined determination of urine uracil levels and plasma 5-FU clearance for a simple order-made treatment with anticancer agents of FU derivative].
    Morimoto S; Mishima H; Tsujinaka T; Kawato N; Shono Y; Tsuji T; Tabuse K; Nakata I; Saito M; Uenaka K
    Gan To Kagaku Ryoho; 2003 Jan; 30(1):89-94. PubMed ID: 12557710
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Design and synthesis of the tumor-activated prodrug of dihydropyrimidine dehydrogenase (DPD) inhibitor, RO0094889 for combination therapy with capecitabine.
    Hattori K; Kohchi Y; Oikawa N; Suda H; Ura M; Ishikawa T; Miwa M; Endoh M; Eda H; Tanimura H; Kawashima A; Horii I; Ishitsuka H; Shimma N
    Bioorg Med Chem Lett; 2003 Mar; 13(5):867-72. PubMed ID: 12617910
    [TBL] [Abstract][Full Text] [Related]  

  • 75. [Support of TS-1, 5-FU preparation containing potent DPD inhibitor by determination of urinary uracil/serum 5-FU clearance].
    Morimoto S; Shono Y; Tsuji T; Makihara K; Kawato N; Hachino Y; Mishima H; Tsujinaka T; Tabuse K
    Gan To Kagaku Ryoho; 2003 Dec; 30(13):2083-9. PubMed ID: 14712769
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Prevention of 5-fluorouracil-induced early severe toxicity by pre-therapeutic dihydropyrimidine dehydrogenase deficiency screening: Assessment of a multiparametric approach.
    Boisdron-Celle M; Capitain O; Faroux R; Borg C; Metges JP; Galais MP; Kaassis M; Bennouna J; Bouhier-Leporrier K; Francois E; Baumgaertner I; Guerin-Meyer V; Cojocarasu O; Roemer-Becuwe C; Stampfli C; Rosenfeld L; Lecompte T; Berger V; Morel A; Gamelin E
    Semin Oncol; 2017 Feb; 44(1):13-23. PubMed ID: 28395758
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Thymidine phosphorylase to dihydropyrimidine dehydrogenase ratio as a predictive factor of response to preoperative chemoradiation with capecitabine in patients with advanced rectal cancer.
    Boskos CS; Liacos C; Korkolis D; Aygerinos K; Lamproglou I; Terpos E; Stoupa E; Baltatzis G; Beroukas K; Papasavvas P; Dimopoulos MA; Bamias A
    J Surg Oncol; 2010 Oct; 102(5):408-12. PubMed ID: 19877119
    [TBL] [Abstract][Full Text] [Related]  

  • 78. 5-Fluorouracil Chemotherapy for Dihydropyrimidine Dehydrogenase-deficient Patients: Potential of the Dose-escalation Method.
    Yoshida Y; Ogura K; Hiratsuka A; Aisu N; Yamada T; Kojima D; Tanimura S; Ogata K; Hara S; Mogi A; Takamatsu Y; Tamura K; Mishima H; Yamashita Y
    Anticancer Res; 2015 Sep; 35(9):4881-7. PubMed ID: 26254383
    [TBL] [Abstract][Full Text] [Related]  

  • 79. [Severe toxicity following capecitabine administration because of dihydropyrimidine deshydrogenase (DPD) deficiency].
    Coursier S; Martelet S; Guillermet A; Emptoz J; Villier C; Bontemps H
    Gastroenterol Clin Biol; 2010 Mar; 34(3):218-23. PubMed ID: 20219304
    [TBL] [Abstract][Full Text] [Related]  

  • 80. New advances in DPYD genotype and risk of severe toxicity under capecitabine.
    Etienne-Grimaldi MC; Boyer JC; Beroud C; Mbatchi L; van Kuilenburg A; Bobin-Dubigeon C; Thomas F; Chatelut E; Merlin JL; Pinguet F; Ferrand C; Meijer J; Evrard A; Llorca L; Romieu G; Follana P; Bachelot T; Chaigneau L; Pivot X; Dieras V; Largillier R; Mousseau M; Goncalves A; Roché H; Bonneterre J; Servent V; Dohollou N; Château Y; Chamorey E; Desvignes JP; Salgado D; Ferrero JM; Milano G
    PLoS One; 2017; 12(5):e0175998. PubMed ID: 28481884
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.